Characterization of antisense oligonucleotides comprising 2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid (FANA): specificity, potency, and duration of activity

Antisense oligonucleotides (AON) are being developed for a wide array of therapeutic applications. Significant improvements in their serum stability, target affinity, and safety profile have been achieved with the development of chemically modified oligonucleotides. Here, we compared 2'-deoxy-2...

Full description

Saved in:
Bibliographic Details
Published in:Annals of the New York Academy of Sciences 2006-10, Vol.1082 (1), p.91-102
Main Authors: Ferrari, Nicolay, Bergeron, Denis, Tedeschi, Anna-Lisa, Mangos, Maria M, Paquet, Luc, Renzi, Paolo M, Damha, Masad J
Format: Article
Language:English
Subjects:
Arabinonucleotides - pharmacology
Drug Stability
Gene Silencing
HeLa Cells
Humans
Inhibitory Concentration 50
Luciferases - antagonists & inhibitors
Luciferases - genetics
Oligonucleotides, Antisense - chemistry
Oligonucleotides, Antisense - pharmacology
RNA, Small Interfering - pharmacology
Structure-Activity Relationship
Thionucleotides - pharmacology
Time Factors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Antisense oligonucleotides (AON) are being developed for a wide array of therapeutic applications. Significant improvements in their serum stability, target affinity, and safety profile have been achieved with the development of chemically modified oligonucleotides. Here, we compared 2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid (FANA)-containing AONs with phosphorothioate oligodeoxynucleotides (PS-DNA), 2'-O-methyl-RNA/DNA chimeras and short interfering RNAs (siRNA) with respect to their target knockdown efficacy, duration of action and resistance to nuclease degradation. Results show that two different configurations of FANA/DNA chimeras (altimers and gapmers) were found to have potent antisense activity. Specific target inhibition was observed with both FANA configurations with an estimated EC50 value comparable to that of an siRNA but 20-to 100-fold lower than the other commonly used AONs. Moreover, the FANA/DNA chimeras showed increased serum stability that was correlated with sustained antisense activity for up to 4 days. Taken together, these results indicate that chimeric FANA/DNA AONs are promising new tools for therapeutic gene silencing when increased potency and duration of action are required.
ISSN:0077-8923
1749-6632
DOI:10.1196/annals.1348.032